Danaher (DHR) Stock Forecast & Price Target

$200.70 +1.07 (+0.54%)

Closing price 07/8/2025 03:59 PM Eastern

Extended Trading

$200.86 +0.16 (+0.08%)

As of 07/8/2025 07:47 PM Eastern

Danaher - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
4

Buy
16

Based on 20 Wall Street analysts who have issued ratings for Danaher in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 4 have given a hold rating, and 16 have given a buy rating for DHR.

Consensus Price Target

$248.00
23.57% Upside

According to the 20 analysts' twelve-month price targets for Danaher, the average price target is $248.00. The highest price target for DHR is $315.00, while the lowest price target for DHR is $210.00. The average price target represents a forecasted upside of 23.57% from the current price of $200.70.

Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

DHR Analyst Ratings Over Time

Type	Current Forecast 7/9/24 to 7/9/25	1 Month Ago 6/9/24 to 6/9/25	3 Months Ago 4/10/24 to 4/10/25	1 Year Ago 7/10/23 to 7/9/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	18 Buy rating(s)	11 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$248.00	$248.17	$271.33	$268.67
Forecasted Upside	23.57% Upside	24.55% Upside	50.20% Upside	12.03% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Danaher Stock vs. The Competition

Type	Danaher	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.80	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	23.57% Upside	9,181.37% Upside	10.40% Upside
News Sentiment Rating	Very Positive News See Recent DHR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/8/2025	Evercore ISI 2 of 5 stars	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$230.00 ➝ $226.00	+13.23%
6/24/2025	Barclays 3 of 5 stars	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $225.00	+14.20%
6/5/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Lower Target		$240.00 ➝ $235.00	+22.45%
4/25/2025	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$270.00 ➝ $240.00	+21.41%
4/23/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight	$240.00 ➝ $210.00	+6.86%
4/23/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$225.00 ➝ $230.00	+17.04%
4/23/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$240.00 ➝ $248.00	+26.20%
4/23/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $240.00	+22.13%
4/23/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Conor McNamara Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$250.00 ➝ $250.00	+25.71%
4/23/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Sykes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$260.00 ➝ $240.00	+20.47%
Get the Latest News and Ratings for DHR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.
4/23/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00	+25.19%
4/23/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$275.00 ➝ $240.00	+17.66%
4/23/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Catherine Schulte Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$231.00 ➝ $225.00	+17.15%
4/22/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tycho Peterson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$260.00 ➝ $230.00	+19.75%
4/22/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tycho Peterson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$280.00 ➝ $260.00	+35.37%
4/14/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$265.00 ➝ $230.00	+19.16%
4/7/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
4/7/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$275.00 ➝ $220.00	+21.74%
3/14/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$260.00	+27.48%
2/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
12/23/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$265.00	+15.95%
10/23/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$315.00 ➝ $315.00	+23.29%
10/23/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$290.00 ➝ $310.00	+19.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:05 AM ET.

Should I Buy Danaher Stock? DHR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 6, 2025. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

Danaher
Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

The current stock price is around $196.74, which may present a buying opportunity for investors looking for growth in the healthcare and industrial sectors.
Danaher Co. has a low dividend payout ratio of 24.85%, indicating that the company retains a significant portion of its earnings for reinvestment, which could lead to future growth.
Recent analyst ratings show a consensus rating of "Moderate Buy" with a target price of approximately $248.61, suggesting potential upside for investors.
Seventeen analysts have assigned a buy rating to Danaher Co., reflecting strong confidence in the company's future performance.
The company has a diverse portfolio of professional, medical, industrial, and commercial products, which can help mitigate risks associated with market fluctuations.

Danaher
Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

Some analysts have recently downgraded their target prices, with Wells Fargo reducing theirs to $210.00, indicating potential concerns about short-term performance.
Insider selling has been observed, with significant shares sold by executives, which could signal a lack of confidence in the company's near-term prospects.
The stock has experienced fluctuations, and the recent decrease in the chairman's position by 28.70% may raise red flags for potential investors.
With four analysts rating the stock as a hold, there may be uncertainty about the stock's ability to outperform the market in the near future.
Market conditions can be volatile, and Danaher Co.'s performance may be affected by broader economic factors that could impact its diverse product lines.

DHR Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Danaher is $248.00, with a high forecast of $315.00 and a low forecast of $210.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DHR shares.
: According to analysts, Danaher's stock has a predicted upside of 23.57% based on their 12-month stock forecasts.
: Over the previous 90 days, Danaher's stock had 1 upgrade by analysts.
: Danaher has been rated by research analysts at Argus, Bank of America, Barclays, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Robert W. Baird, Royal Bank Of Canada, TD Cowen, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Danaher less than other "medical" companies. The consensus rating score for Danaher is 2.80 while the average consensus rating score for "medical" companies is 2.80. Learn more on how DHR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:DHR) was last updated on 7/9/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Danaher (DHR) Stock Forecast & Price Target